CALAN SR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Calan Sr, and when can generic versions of Calan Sr launch?
Calan Sr is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in CALAN SR is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Calan Sr
A generic version of CALAN SR was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
Summary for CALAN SR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 146 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CALAN SR |
| What excipients (inactive ingredients) are in CALAN SR? | CALAN SR excipients list |
| DailyMed Link: | CALAN SR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CALAN SR
US Patents and Regulatory Information for CALAN SR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | CALAN SR | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019152-003 | Mar 6, 1991 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Pfizer | CALAN SR | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019152-002 | Dec 15, 1989 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Pfizer | CALAN SR | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019152-001 | Dec 16, 1986 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
